Cognitive impairment in testicular cancer survivors 2 to 7 years after treatment

• Published in: Supportive care in cancer Vol. 23; no. 10; pp. 2973 - 2979
• Main Authors: Amidi, Ali, Wu, Lisa M., Pedersen, Anders Degn, Mehlsen, Mimi, Pedersen, Christina Gundgaard, Rossen, Philip, Agerbæk, Mads, Zachariae, Robert
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.10.2015; Springer; Springer Nature B.V
• Subjects: Adult; Aged; Batteries; Cancer; Cancer therapies; Chemotherapy; Cognition Disorders - diagnosis; Cognition Disorders - etiology; Cognitive ability; Comparative analysis; Follow-Up Studies; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasms, Germ Cell and Embryonal - complications; Neuropsychological Tests; Nursing; Nursing Research; Oncology; Original Article; Pain Medicine; Quality of Life; Rehabilitation Medicine; Survivors; Testicular cancer; Testicular Neoplasms - complications; Young Adult; Cognition function; Neuropsychological testing; Testicular cancer; Cognitive impairment; Quality of life
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-015-2663-3

Purpose The aim of the present study was to determine the prevalence of cognitive impairment (CI) in a group of testicular (TC) survivors by comparing their neuropsychological test scores with normative data and to assess their performance in specific cognitive domains. Methods Seventy-two TC survivors were evaluated 2 to 7 years post-treatment with a neuropsychological test battery that assessed multiple cognitive domains—attention and working memory, processing speed, verbal fluency, learning and memory, and executive functioning. Test scores were compared with normative data, and CI status was calculated for each participant. Results In group-level analyses, survivors exhibited significantly impaired scores on a majority (9/12) of the neuropsychological outcomes ( p  < 0.01). In individual-level analyses, 62.5 % of the survivors were classified as having CI, significantly exceeding the expected normative frequency of 25 % (binomial test: p  < 0.001). In particular, CI was observed in multiple outcomes related to verbal learning and memory (29 to 33 % of participants), visual learning and memory (14–28 %), processing speed (8–24 %), executive functioning (17 %), and attention and working memory (4–15 %). No association was found between treatment modality (surgery ± chemotherapy) and CI. Conclusions The prevalence of CI in TC survivors was unexpectedly high, with survivors performing significantly worse than expected on a majority of the neuropsychological outcomes. While the findings are preliminary in nature, they still have important implications for the diagnosis and treatment of CI in TC survivors.